De-novo and acquired resistance to immune checkpoint targeting
- PMID: 29208439
- DOI: 10.1016/S1470-2045(17)30607-1
De-novo and acquired resistance to immune checkpoint targeting
Abstract
Use of immune checkpoint inhibitors targeting the programmed cell death protein-1/programmed cell death-ligand 1 and cytotoxic T lymphocyte-associated protein-4 axes has yielded impressive results in some clinical trials. However, only a subset of patients initially respond to these inhibitors, and increasing clinical evidence indicates that a substantial proportion of initial responders ultimately relapse with lethal, drug-resistant disease months or years later. Studies that have used massively parallel sequencing have shed light on the rich functional landscape of mutations that endow tumour cells with the ability to evade T-cell-mediated immunosurveillance. Cancer genomes bear signatures of clonal evolution and selection, particularly implicating acquired defects in interferon receptor signalling and antigen presentation. In this Review, we discuss the biological processes that operate in the formation of so-called immunoresistant niches, and describe the latest progress in the development of combination strategies to reinstate immunosurveillance in immune-refractory tumours.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?Bull Cancer. 2019 Feb;106(2):105-113. doi: 10.1016/j.bulcan.2018.08.007. Epub 2018 Oct 17. Bull Cancer. 2019. PMID: 30342749 Review.
-
Biomarkers of response to immune checkpoint blockade in cancer treatment.Crit Rev Oncol Hematol. 2018 Oct;130:108-120. doi: 10.1016/j.critrevonc.2018.07.010. Epub 2018 Aug 3. Crit Rev Oncol Hematol. 2018. PMID: 30196907 Review.
-
New checkpoint inhibitors ride the immunotherapy tsunami.Nat Rev Drug Discov. 2013 Jul;12(7):489-92. doi: 10.1038/nrd4066. Nat Rev Drug Discov. 2013. PMID: 23812256 No abstract available.
-
Progress of immune checkpoint therapy in the clinic (Review).Oncol Rep. 2019 Jan;41(1):3-14. doi: 10.3892/or.2018.6819. Epub 2018 Oct 24. Oncol Rep. 2019. PMID: 30365127 Review.
-
PD-1/PD-L1 and immunotherapy for pancreatic cancer.Cancer Lett. 2017 Oct 28;407:57-65. doi: 10.1016/j.canlet.2017.08.006. Epub 2017 Aug 18. Cancer Lett. 2017. PMID: 28826722 Review.
Cited by
-
New anti-cancer explorations based on metal ions.J Nanobiotechnology. 2022 Oct 23;20(1):457. doi: 10.1186/s12951-022-01661-w. J Nanobiotechnology. 2022. PMID: 36274142 Free PMC article. Review.
-
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities.Exp Hematol Oncol. 2022 Nov 16;11(1):101. doi: 10.1186/s40164-022-00356-0. Exp Hematol Oncol. 2022. PMID: 36384676 Free PMC article. Review.
-
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.Br J Cancer. 2020 Sep;123(6):885-897. doi: 10.1038/s41416-020-0994-4. Epub 2020 Jul 27. Br J Cancer. 2020. PMID: 32713938 Free PMC article. Review.
-
Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.Int J Mol Sci. 2020 Jul 6;21(13):4778. doi: 10.3390/ijms21134778. Int J Mol Sci. 2020. PMID: 32640548 Free PMC article.
-
Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia.Pharmacol Res. 2024 Jan;199:107048. doi: 10.1016/j.phrs.2023.107048. Epub 2023 Dec 23. Pharmacol Res. 2024. PMID: 38145833 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials